News | Women's Health | July 21, 2015

Scientific study confirms reduced variation between exam results with automated density measurements

July 21, 2015 - Researchers at the University of Virginia (UVA) Health System have demonstrated that automated volumetric fibroglandular breast density measurement tools are more precise than area-based methods.  Results of the study, "Reliability of Automated Breast Density Measurements," recently featured in Radiology, suggest that with lower variability, volumetric breast density is well suited for inclusion in breast cancer risk models. The announcement was made at The Association for Medical Imaging Management (AHRA)'s 43rd annual meeting and exposition, July 19-22 in Las Vegas. 

"Breast density is increasingly being considered with other known risk factors to improve risk prediction in order to give women personalized knowledge to make decisions about screening. However, variability in assigned density category may result in changes in recommendations for adjuvant screening. Thus, for consistency, objectivity, and ease of use, breast density measurement ideally should be automated and accurate," said Jennifer Harvey, M.D., professor of radiology at the UVA School of Medicine. "The purpose of this study was to estimate the reliability of area-based methods and automated volumetric breast density measurements using repeated measures."

Thirty women undergoing screening mammography consented to undergo a repeated left craniocaudal examination performed by a second technologist in this prospective study. Breast density was measured by using both area-based and volumetric methods (Volpara software). Discrepancy between the first and second breast density measurements was obtained for each algorithm by subtracting the second measurement from the first and then analyzed with a random-effects model to derive limits of measurement agreement. 

Results of the study demonstrate that variability in a repeated measurement of breast density is highest for area-based measurement tools, standard deviation 3.32 percent (2.65-4.44). In contrast, precision was highest for automated volumetric breast density tools, such as VolparaDensity, standard deviation 0.99 percent (0.79-1.33).  

"The excellent reproducibility of automated breast density measurements indicates that they would be well suited for inclusion in a breast cancer risk model.  This is consistent with results we presented at the San Antonio Breast Cancer Symposium in December that showed that the addition of volumetric breast density improved breast cancer risk discrimination," Harvey added.

For more information: www.uvahealth.com


Related Content

News | Magnetic Resonance Imaging (MRI)

July 7, 2026 — Imagion Biosystems, Ltd. recently announced it has renewed and extended its collaboration agreement with ...

Time July 07, 2026
arrow
News | Breast Imaging

July 7, 2026 — QT Imaging Holdings, Inc. recently announced it has successfully completed its first routine inspection ...

Time July 07, 2026
arrow
News | MRI Breast

July 2, 2026 – Quibim has announced the European and UK launch of QP-Breast, its CE and UKCA-marked AI tool which ...

Time July 02, 2026
arrow
News | Mammography

June 30, 2026 — The Food and Drug Administration has cleared new contrast-enhanced mammography (CEM) and CEM biopsy ...

Time June 30, 2026
arrow
News | Mammography

June 23, 2026 — Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer ...

Time June 24, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

June 9, 2026 — An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for ...

Time June 15, 2026
arrow
News | Women's Health

June 2, 2026 — Results of an American College of Radiology-managed retrospective study involving 110,000 women presented ...

Time June 02, 2026
arrow
News | Ultrasound Imaging

May 26, 2026 — A soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time — and it can ...

Time May 27, 2026
arrow
News

May 21, 2026 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 22, 2026
arrow
News | FDA

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time May 07, 2026
arrow
Subscribe Now